Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 2021 Jun 2;125(3):465. doi: 10.1038/s41416-021-01403-z

Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

Thomas Decaens 1,, Carlo Barone 2, Eric Assenat 3, Martin Wermke 4, Angelica Fasolo 5, Philippe Merle 6, Jean-Frédéric Blanc 7, Véronique Grando 8, Angelo Iacobellis 9, Erica Villa 10, Joerg Trojan 11, Josef Straub 12, Rolf Bruns 13, Karin Berghoff 14, Juergen Scheele 15, Eric Raymond 16, Sandrine Faivre 17
PMCID: PMC8329044  PMID: 34079081

Correction to: British Journal of Cancer 10.1038/s41416-021-01334-9, published online 6 April 2021

The original version of this article unfortunately contained a mistake. Due to a typesetting error ‘sorafenib pretreated’ was changed to ‘sorafenibpretreated’ throughout the article. The correct spelling is ‘sorafenib pretreated. There were also minor errors in Fig. 1 and Fig. 3. The original article has been corrected.


Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES